Month: September 2021

Geneva, Switzerland, September 8, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference (September 13 – 15, 2021). In his presentation, which is scheduled for Monday, September 13, 2021 at 07:00 ET / 13:00 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing on-demand by registered participants via this link from the time of the presentation and subsequently on the Events page the Company’s website (www.addextherapeutics.com). The video replay will be archived for 90 days following the event. Management will be available for virtual...

Sanofi to acquire Kadmon to further strengthen growth of transplant businessAdds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapyPARIS and NEW YORK – September 8, 2021 – Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. (NASDAQ: KDMN) a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs. The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock™(belumosudil) to its transplant portfolio. Rezurock is a recently FDA-approved, first-in-class treatment for chronic graft-versus-host...

Pixium Vision expands collaboration with Stanford University on next generation Prima System implantsNew implants to leverage existing PRIMA design and significantly improve implant resolution Collaboration expands existing agreement between Pixium Vision and Stanford UniversityParis, France, September 8, 2021 – 07.00 CET– Pixium Vision SA (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today expansion of collaboration with the academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration (AMD). “We are very excited to be extending our collaboration with Stanford University, with whom...

REGULATED INFORMATION The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Bone Therapeutics in the section ‘Financial information’. Bone Therapeutics publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report, the original English version will prevail.   Concentrating focus on the continued development and expansion of the mesenchymal stromal cell based allogeneic cell and gene therapy platform Strengthens financial position with the release of the first tranche of EUR 8.0 million as part of the financing agreement with EIB   Management...

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced today it is scheduled to host a virtual research and development day focused on its product candidate ANG-3070, a novel, highly selective, and orally-bioavailable small molecule tyrosine kinase receptor inhibitor in clinical development for the treatment of fibrotic diseases, including those in the kidney and lung, at 10:00am EDT on Monday, September 20th. The event will feature presentations by two medical experts, including Joseph V. Bonventre, M.D., Ph.D., Harvard Medical School, who will discuss the current treatment landscape and unmet medical...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announces the filing of the Company’s unaudited interim financial statements for the three month period ended March 31, 2021, and accompanying management’s discussion and analysis, and related certifications ‎‎(collectively, the “Documents”). Electronic copies of the Documents are available on SEDAR (www.sedar.com) under the Company’s issuer profile. The...

San Diego, California, Sept. 07, 2021 (GLOBE NEWSWIRE) — HUMBL, Inc. (OTC Markets: HMBL) is excited to announce the launch of its HUMBL NFT Gallery for the creation, listing, sale, and purchase of Non-Fungible Tokens (NFTs) on the blockchain. The HUMBL NFT Gallery will pilot launch over 15 original collections, including Smallz + Raskind, Fulton Hobbs, Des Tayor, and others across a variety of collectible digital media, with artist representation from the United States, Canada, Mexico, Australia, U.K., and Israel. Global customers will be able to view, purchase and sell NFTs at www.HUMBLPay.com, alongside NFT publishing and storage tools such as video tutorials and wallet plugins. HUMBL will also be offering white glove creative services to select clients across a variety of industries. The company will be partnering with clients...

TORONTO and BROSSARD, Québec, Sept. 07, 2021 (GLOBE NEWSWIRE) — Bitfarms Ltd. (Nasdaq: BITF // TSXV: BITF), a publicly traded Bitcoin mining company currently powering over 1% of the Bitcoin network with greater than 99% green hydroelectricity, announces today it has reached an agreement with the City of Sherbrooke, Québec, on a comprehensive agreement to develop 96 MW of hydropower on an expedited basis. The agreement with the City advances the Company’s growth goals of 3 Exahash by first quarter 2022 and 8 Exahash by year-end 2022 while addressing residential concerns about sound emissions. Under the agreement, Bitfarms’ current operations in the City of Sherbrooke on Rue de la Pointe will be replaced by new, high efficiency facilities with next-generation mining equipment optimized for higher output levels and lower power consumption....

BANNOCKBURN, Ill., Sept. 07, 2021 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH) announced today that an affiliate of Madison Dearborn Partners (the “Selling Stockholder”) has agreed to sell 9,200,000 shares of the Company’s common stock at a price to the public of $26.90 per share in an underwritten public offering. The offering is expected to close on September 9, 2021, subject to customary closing conditions. The Company will not receive any proceeds from the offering. This sale of shares represents approximately 5.1% of the current shares outstanding. Upon completion of this offering, the Selling Stockholder’s interest in the Company will be reduced to 21.1% of the outstanding shares, from the current 26.2%. Consistent with the August 2021 secondary offering, Madison Dearborn...

GAHC Sees Support Grow for Pending Acquisitions and Partnerships with Majority Of Stockholders Supporting An Increase In Authorized Shares and Reverse Stock Split New York, NY, Sept. 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Global Arena Holding, Inc. (the “Company”) (OTC PINK: GAHC), announced today that Company completed its Annual Stockholders’ Meeting (the “Annual Meeting”) on September 7, 2021, with all of the proposals receiving majority support from the Company’s stockholders.  Management indicated that 62.76% of the Company’s stockholders participated in this year’s Annual Meeting.  As noted in the Proxy Packet, the proposals being voted on at this year’s Annual Meeting were:  ·      Re-election of members to the Board of Directors. ·      Authorization of an increase in the Company’s authorized capital stock. ·      Authorization...